Leveraging Synthetic Biology for Resilient Pharma Supply Chains and Accessible Medicines
Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Live at SynBioBeta
Each year, SynBioBeta hosts the The Global Synthetic Biology Conference to showcase the latest cutting-edge developments in biology that are changing how we solve global problems. As a proud sponsor of this year’s event, we look forward to connecting with the synthetic biology community and sharing our progress toward transforming pharmaceutical supply chains.
Advancing the U.S. Bioeconomy and Building Resilient Pharmaceutical Supply Chains
We continue to see the U.S. government setting policy priorities that underscore the importance of both building a robust American bioeconomy and strengthening domestic pharmaceutical supply chains – two core pillars of Antheia’s business and technology.
Synthetic Chemistry in Pharma
Synthetic chemistry is an essential part of drug development, opening the door for scientists to create complex small molecules with specific properties. Small molecule drugs – including household staples like aspirin and acetaminophen – currently make up the bulk of approved pharmaceuticals to date.
Introducing Jesse Ahrendt, Antheia’s SVP of Quality Assurance & Regulatory Affairs
We’ve recently welcomed Jesse Ahrendt, our new Senior Vice President of Quality Assurance and Regulatory Affairs, who will lead our quality and regulatory efforts. He brings 25 years of experience…
Synthetic Biology vs Synthetic Chemistry: A Primer
At Antheia, we spend a lot of time talking about synthetic biology due to the nature of our work engineering yeast to produce active pharmaceutical ingredients (APIs) and key starting materials (KSMs)…
Antheia’s 2022 in Review: A Year of Value
This year has been ripe with growth, major achievements, and opportunities to showcase who and what make Antheia the visionary business it is. Nearly eight years ago, we co-founded Antheia…
Demystifying Synthetic Biology Part V: The Product is Key in Downstream Processing
Upstream bioprocessing – better known in biomanufacturing as fermentation – is directly followed by downstream bioprocessing (DSP). Just as fermentation is all about maximizing the production of a target compound, DSP focuses
Introducing Guerin Kob, Antheia’s VP of Supply Chain
With a pilot plant on the horizon and a pipeline filled with promise, Antheia is poised to soon establish a fermentation-based supply chain to produce the KSMs and APIs for essential medicines.
Demystifying Synthetic Biology IV: Fermentation Bioprocess Development
Fermentation is one of humanity’s oldest and most pivotal technological developments. Through fermentation, societies began adapting their diets nearly ten millennia ago, to include new and innovative foods such as alcohol and leavened bread…